Cannabis Science Anticipates Marijuana Legalization as Latest Polls Show Legalization Leading 49% in Favor With 41% Opposed; Los Angeles City Efforts to Close Medical Dispensaries Will Help Drive to End Prohibition

June 8, 2010

COLORADO SPRINGS, Colo. - Cannabis Science, Inc. (OTCBB:CBIS - News), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to report that recent polls in California show 49% in favor of the legalization of marijuana with 41% opposed. This percentage is likely to increase due to the recent move by the city of Los Angeles closing roughly 400 medical marijuana dispensaries yesterday. With these closures, and an outraged group of patients, Cannabis Science is looking forward to seeing this large community of medical marijuana users demanding their personal rights to use medical marijuana in the upcoming vote for full legalization this November.

Richard Cowan, Cannabis Science CFO, and like Dr. Robert Melamede, PhD., Cannabis Science President and CEO a long-time advocate of the legalization of marijuana, noted, "We certainly think that the move to close so many medical marijuana dispensaries in Los Angeles is likely to increase the majorities in favor of the legalization initiative in the fall. We believe that only full legalization will protect the patients and the public. Marijuana prohibition is a public health disaster and Cannabis Science is happy to be in a position to advance the science of medical cannabis and continue to be an ongoing resource for all our patients in need."

Dr. Melamede continues, "Although Cannabis Science regrets the misfortune imposed on the patients of the 400 medical marijuana dispensaries that are facing closure, the Company sees this as all the more reason to continue on its path as a leader in research and development of medical cannabis products. Cannabis Science is anticipating the legalization of marijuana progressing over the next few years, but it is still moving forward with its plans to develop standardized pharmaceutical cannabis products for FDA approval."

Dr. Melamede concludes with, "The opportunity for Cannabis Science as a leading force in the medical marijuana industry continues to grow significantly. In addition to all the new business ventures that have presented themselves, Cannabis Science has continued to move forward with our primary focus and goals, preliminary patent disclosures as well as the acquisition of a private Biopharmaceutical Company for the development of new patentable products. Things are progressing very quickly for us as the company moves forward with its multiple joint ventures and acquisitions. We are sure to be in for an exciting time for everyone involved. We look forward to making these announcements soon."

Cannabis Science Inc.
Cannabis Science is at the forefront of pharmaceutical medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

CONTACT
Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888

Investor Relations
Mark J. Freedman
1.877.431.CBIS
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.cannabisscience.com